Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration

Larsen, Michael; Schmidt‐Erfurth, Ursula; Lanzetta, Paolo; Wolf, Sebastian; Simader, Christian; Tokaji, Erika; Pilz, Stefan; Weisberger, Annemarie

doi:10.1016/j.ophtha.2012.02.002

Cited by 119 publications

(93 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10] Increasing the dose of ranibizumab was efficacious in some patients. 11 After the FDA approval of ranibizumab, several groups reported about a switch from bevacizumab to ranibizumab 12,13 and found a comparable effect after the switch, though not only nonresponders were included.…”

Section: Introductionmentioning

confidence: 99%

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Ehlken

Jungmann

Böhringer

et al. 2014

Eye

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Ehlken

Jungmann

Böhringer

et al. 2014

Eye

View full text Add to dashboard Cite

“…In addition, fewer than 3 lines of loss in vision were revealed at 70.8% and 33.3% in the combination and PDT monotherapy groups, respectively (20). The MONT BLANC study (21) and the DENALI study (22) compared the results of combination therapy of verteporfin PDT and intravitreal ranibizumab versus ranibizumab monotherapy in patients with AMD-related subfoveal CNV. The mean BCVA gains in the combination therapy and monotherapy group were 2.5 and 4.4 letters in the MONT BLANC study (21) and 5.3 and 8.1 letters in the DENALI study (22), respectively.…”

Section: Discussionmentioning

confidence: 99%

Comparative study of photodynamic therapy monotherapy versus triplemanagement in age-related macular degeneration

Selim¹,

Koçak²,

Aslankara³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

Aim: To compare the effectiveness of photodynamic therapy (PDT) and PDT combined with intravitreal triamcinolone (IVTA) and vascular endothelial growth factor inhibition (anti-VEGF) in age-related macular degeneration (AMD).Materials and methods: Eighty eyes of 80 patients diagnosed with choroidal neovascularization (CNV) caused by AMD were included in the study. PDT was carried out on 40 eyes in group I, and PDT combined with 4 mg IVTA and anti-VEGF (1.25 mg bevacizumab in 20 eyes, 0.3 mg pegaptanib sodium in 20 eyes) was carried out in group II. The primary efficacy endpoint was the mean change from baseline visual acuity at month 12.Results: Mean follow-up was 14.2 ± 2.18 months in group I and 12.45 ± 2.82 months in group II. In group I there was a 2.88 logMAR line decrease and 1.95 logMAR line increase in group II in vision between pretreatment and 12th month measurements (P < 0.05). Mean PDT session was 2.00 in group I and the mean combined treatment session was 1.15 in group II in the 12th month. Conclusion:Combination of IVTA and anti-VEGF with PDT is more effective and safer than PDT monotherapy in the treatment of CNV secondary to AMD. Combination treatment decreases the frequency and number of treatment sessions for an improved visual prognosis.

show abstract

“…Studies investigating combination PDT and anti-VEGF therapy for AMD did not show benefit with respect to visual acuity or significant reduction in number of injections Larsen et al 2012).…”

Section: Combination Therapymentioning

confidence: 94%

Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration

Yonekawa

Kim

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a multifactorial degeneration of photoreceptors and retinal pigment epithelium. The societal impact is significant, with more than 2 million individuals in the United States alone affected by advanced stages of AMD. Recent progress in our understanding of this complex disease and parallel developments in therapeutics and imaging have translated into new management paradigms in recent years. However, there are many unanswered questions, and diagnostic and prognostic precision and treatment outcomes can still be improved. In this article, we discuss the clinical features of AMD, provide correlations with modern imaging and histopathology, and present an overview of treatment strategies.

show abstract

Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration

Cited by 119 publications

References 23 publications

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Comparative study of photodynamic therapy monotherapy versus triplemanagement in age-related macular degeneration

Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration

Contact Info

Product

Resources

About